Yahoo Finance

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate ...
UploadVR

Beat Saber Confirms OST 8 Launch This November

Beat Saber will receive OST 8 next month, marking the first OST release in over a year. As a reminder, these Beat Saber tracks won't be available on either PlayStation VR or PlayStation VR2. Meta ...
Yahoo Finance

OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting

OS Therapies on track to complete clinical data submission by the end of Q1 2026 New York, New York--(Newsfile Corp. - March 9, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the ...
BioSpace

FDA aligns with MHRA and EMA on adaptive design for Phase 3 trial

FDA aligns with MHRA and EMA on adaptive design for Phase 3 trial • After successful Scientific Advice Meeting, Company ...
Business Wire

OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer

ROCKVILLE, Md.--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic ...